• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人白细胞尿激酶抑制剂——纯化、特性鉴定及与不同纤溶酶原激活剂的比较研究

Human leucocyte urokinase inhibitor--purification, characterization and comparative studies against different plasminogen activators.

作者信息

Kopitar M, Rozman B, Babnik J, Turk V, Mullins D E, Wun T C

出版信息

Thromb Haemost. 1985 Dec 17;54(4):750-5.

PMID:3879018
Abstract

A plasminogen activator inhibitor (PA-I) which inhibits primarily plasminogen activator of the urokinase type (u-PA) was isolated from the cytosol of human peripheral leukocytes. The inhibitor was isolated using ion exchange chromatography, gel filtration and FPLC. This inhibitor has an apparent molecular weight of 45 kDa, determined by SDS-PAGE, and a pI of 5.5-5.7. The inhibitor is a fast reacting inhibitor, is thermally unstable and is inactivated outside the pH range 7-9. Treatment of cytosol to pH 9 for 30 min at 37 degrees C resulted in a large increase in inhibitory activity. Antibodies against human placental UK-I completely quenched the inhibitory activity of human leucocyte UK-I.

摘要

从人外周血白细胞胞质溶胶中分离出一种主要抑制尿激酶型纤溶酶原激活剂(u-PA)的纤溶酶原激活剂抑制剂(PA-I)。该抑制剂通过离子交换色谱、凝胶过滤和快速蛋白质液相色谱法进行分离。通过SDS-PAGE测定,该抑制剂的表观分子量为45 kDa,pI为5.5 - 5.7。该抑制剂是一种快速反应抑制剂,热不稳定,在pH范围7 - 9之外会失活。在37℃将胞质溶胶处理至pH 9 30分钟会导致抑制活性大幅增加。针对人胎盘UK-I的抗体完全消除了人白细胞UK-I的抑制活性。

相似文献

1
Human leucocyte urokinase inhibitor--purification, characterization and comparative studies against different plasminogen activators.人白细胞尿激酶抑制剂——纯化、特性鉴定及与不同纤溶酶原激活剂的比较研究
Thromb Haemost. 1985 Dec 17;54(4):750-5.
2
Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator.用单克隆抗体纯化特异性胎盘纤溶酶原激活物抑制剂及其与纤溶酶原激活物的复合物形成
Thromb Haemost. 1985 Feb 18;53(1):122-5.
3
Human articular cartilage contains an inhibitor of plasminogen activator.人体关节软骨含有纤溶酶原激活物的抑制剂。
J Rheumatol. 1988 Jul;15(7):1138-43.
4
The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase.血浆中组织型纤溶酶原激活物的快速作用抑制剂也是尿激酶的主要血浆抑制剂。
Thromb Haemost. 1986 Feb 28;55(1):65-9.
5
Purification and characterization of placental plasminogen activator (PPA).
Nihon Sanka Fujinka Gakkai Zasshi. 1985 May;37(5):783-92.
6
Isolation of peptides with anti-urokinase activity from the human placenta.从人胎盘中分离具有抗尿激酶活性的肽。
Thromb Haemost. 1980 Feb 29;42(5):1411-6.
7
Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells--inhibitor neutralization and one-step affinity purification.来自纤维肉瘤细胞的针对人54000分子量纤溶酶原激活物抑制剂的单克隆抗体——抑制剂中和及一步亲和纯化
Thromb Haemost. 1986 Apr 30;55(2):206-12.
8
Immunological relationship between the fast-acting plasminogen activator inhibitors from plasma, blood platelets and endothelial cells demonstrated with a monoclonal antibody against an inhibitor from placenta.用抗胎盘来源抑制剂的单克隆抗体证明血浆、血小板和内皮细胞中快速作用的纤溶酶原激活物抑制剂之间的免疫学关系。
Thromb Haemost. 1986 Apr 30;55(2):213-7.
9
Kinetics of the inhibition by plasminogen activator inhibitor 2 of urokinase isolated from human urine and recombinant microorganisms. Further evidence for correct tertiary structure of recombinant urokinase.纤溶酶原激活物抑制剂2对从人尿及重组微生物中分离的尿激酶的抑制动力学。重组尿激酶正确三级结构的进一步证据。
Arzneimittelforschung. 1988 Aug;38(8):1196-8.
10
Effects of castration on plasminogen activator activities and plasminogen activator inhibitor type 1 in the rat ventral prostate.去势对大鼠前列腺腹叶纤溶酶原激活物活性及1型纤溶酶原激活物抑制剂的影响。
Prostate. 1996 Apr;28(4):239-50. doi: 10.1002/(SICI)1097-0045(199604)28:4<239::AID-PROS5>3.0.CO;2-8.

引用本文的文献

1
Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis.2型纤溶酶原激活物抑制剂在正常和银屑病表皮中的表达。
Histochemistry. 1994 Feb;101(2):105-12. doi: 10.1007/BF00269356.
2
Cellular and extracellular plasminogen activator and inhibitor in an experimental tumour.实验性肿瘤中的细胞和细胞外纤溶酶原激活剂及抑制剂
Br J Exp Pathol. 1988 Oct;69(5):685-95.
3
Glucocorticoid-modulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2.糖皮质激素对组织型和尿型纤溶酶原激活物以及纤溶酶原激活物抑制剂1和2基因表达的调节作用
J Cell Biol. 1988 Mar;106(3):971-8. doi: 10.1083/jcb.106.3.971.
4
Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts.转化生长因子-β是WI-38人肺成纤维细胞中1型纤溶酶原激活物抑制剂mRNA水平的一种强效且作用迅速的正向调节因子。
EMBO J. 1987 May;6(5):1281-6. doi: 10.1002/j.1460-2075.1987.tb02365.x.
5
Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells.佛波酯在人U - 937淋巴瘤细胞中诱导糖基化和非糖基化纤溶酶原激活物抑制剂2的生物合成,其过量程度远超过尿激酶型纤溶酶原激活物。
J Cell Biol. 1987 Mar;104(3):705-12. doi: 10.1083/jcb.104.3.705.
6
Plasminogen activator-specific inhibitors produced by human monocytes/macrophages.人单核细胞/巨噬细胞产生的纤溶酶原激活物特异性抑制剂。
J Exp Med. 1987 Feb 1;165(2):320-39. doi: 10.1084/jem.165.2.320.